1-3 of 3
Betty Lamothe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Sanjay Mohan, Stephen Oh, Jean-Jacques Kiladjian, Masahiro Takeuchi, Jason Gotlib, Ellen K. Ritchie, Taizo Shimomura, Paola Guglielmelli, Anthony M. Hunter, Francesca Palandri, Francoise Boyer, Alessandro Rambaldi, Takehiko Mori, Tomoki Ito, Betty Lamothe, Yan-Ou Yang, Yi Cui, Francis Seguy, Amanda McBride, Prithviraj Bose
Journal: Blood
Blood (2023) 142 (Supplement 1): 624.
https://doi.org/10.1182/blood-2023-179291
Published: 2023
Journal Articles

A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)

Sanjay R Mohan, Stephen T Oh, Haris Ali, Anthony M. Hunter, Francesca Palandri, Betty Lamothe, Yi Cui, Francis Seguy, Amanda McBride, Michael Robert Savona, Jean-Jacques Kiladjian, Srdan Verstovsek
Journal: Blood
Blood (2022) 140 (Supplement 1): 3943–3944.
https://doi.org/10.1182/blood-2022-169210
Published: 2022
Journal Articles

Proteasome inhibitor carfilzomib complements ibrutinib’s action in chronic lymphocytic leukemia

Clinical Trials & Observations
Betty Lamothe, Fabiola Cervantes-Gomez, Mariela Sivina, William G. Wierda, Michael J. Keating, Varsha Gandhi
Journal: Blood
Blood (2015) 125 (2): 407–410.
https://doi.org/10.1182/blood-2014-07-585364
Published: 2015